Actively take measures to deal with the risks three pharmaceutical machinery enterprises achieved first quarter performance growth

[view point of editor of China Pharmaceutical network] the new GMP, the publication of the new medical insurance catalogue, the acceleration of new drug review and approval, and the encouragement of new drug innovation, etc the intensive introduction of pharmaceutical policies put forward higher requirements for pharmaceutical machinery and equipment With the rapid development of science and technology, the pharmaceutical machinery industry has opened the door to the new world 3D printing technology and intelligent chemical plants have provided inexhaustible power for the intelligent, automatic and digital development of pharmaceutical machinery and equipment (take active measures to deal with the risks of the three pharmaceutical machinery enterprises to achieve the growth of the first quarter picture source: Baidu picture) at the end of the first quarter, the business revenue of the three pharmaceutical machinery enterprises to achieve the growth of the 2017 quarter has ended, and pharmaceutical machinery enterprises, such as dongfulong, truking technology, Qianshan pharmaceutical machinery, have released financial reports Compared with 2016, what is the performance of pharmaceutical machinery enterprises? What are the risks faced by pharmaceutical machinery enterprises in the face of tighter policies, higher equipment requirements and the market's preference for innovative equipment? How can we take measures to deal with them? According to the quarterly reports of the three major enterprises, during the reporting period, the operating revenue of DFL in the quarter reached 451 million yuan, an increase of 6.28% year-on-year; the operating revenue of truking technology reached 24%, 9.6998 million yuan, an increase of 22.2509 million yuan or 9.78% over the same period of last year; Qianshan pharmaceutical machinery realized an operating revenue of 241.3292 million yuan, an increase of 20.91% over the same period of last year 2017 is the implementation year of a number of pharmaceutical policy reforms, and the concentration of the pharmaceutical industry has gradually increased Affected by this, the pharmaceutical machinery industry is also facing a transformation and upgrading situation, and enterprises are more or less facing some risks However, from the above three pharmaceutical companies' operating income, the first quarter performance has increased compared with the previous ones According to the analysis of earnings reports, the main reason is that enterprises take timely measures to deal with various risks, accelerate the exploration of Internet plus, improve the application of intelligence and speed up the R & D and production of products In the era of rapid development of Internet and high technology, the market of China's pharmaceutical industry keeps heating up, ushering in a good opportunity for development This "warm wind" also blows to the pharmaceutical machinery industry On this basis, the industry gradually eliminated the low-end and inefficient machinery and equipment, and went to the development road of intelligence and automation However, for the traditional pharmaceutical machinery enterprises, the trend of intelligence and automation is like a strong hand to force enterprises to transform and upgrade If we can't effectively recognize the development trend, actively expand the upgraded product series and extend the industrial chain, the enterprises may be directly affected by the decline in performance In addition to the risks brought by the industry, the market competition is also a "big mountain" on the pharmaceutical machinery enterprises Although China's pharmaceutical machinery and equipment technology has made great progress and development, the homogenization is still serious, and the market competition has entered the white hot stage Moreover, the rapid development of downstream pharmaceutical industry and the increasingly strict GMP certification have an important impact on domestic enterprises However, it is a great advantage for foreign pharmaceutical machinery enterprises in Huabu Bureau Some foreign-funded enterprises gradually accelerate the localization strategic layout of Chinese market, and domestic pharmaceutical machinery enterprises will face adverse market competition In addition, technology is a big risk From the first quarter financial statements of the three major pharmaceutical machinery enterprises, it shows that the enterprises have technical risks The market demand of pharmaceutical machinery is ever-changing, and there is no new equipment and technology but update Compared with domestic, foreign advanced pharmaceutical machinery enterprises have profound technology accumulation and strong R & D strength If local pharmaceutical machinery enterprises can not develop products that follow the trend of technology and meet the needs of domestic and foreign market development, their competitiveness will go from bad to worse Faced with these risks, how should the pharmaceutical enterprises respond? In terms of industry risks, enterprises should formulate strategic plans to avoid risks according to actual conditions, actively upgrade and replace traditional mechanical equipment, improve the situation of relying on traditional business, and explore new business models in the era of "Internet plus" For example, Qianshan medicine machine is integrating resources through the Internet plus chronic disease management service platform to upgrade business mode and enhance risk resistance Truking technology has expanded its product range and increased the sales of new products such as fluid process system, pharmaceutical water system and robot post packaging system At present, the competition in the pharmaceutical machinery market is far more intense than expected, and there is a large gap in intelligent equipment In this regard, pharmaceutical machinery enterprises need to respond to the demand of market intelligence, gradually strengthen innovation, improve technical level, and develop towards the trend of integration, continuity, automation, informatization and intelligence Truking technology is the "pioneer" of intelligence The enterprise actively builds the robot intelligent factory project, promotes the research and development of intelligent pharmaceutical factory, further increases the R & D investment of filling robot, aseptic transfer robot, detection robot and other projects, and realizes batch production For the rapid technological risks in the industry, pharmaceutical machinery enterprises need to improve innovation ability and maintain competitive advantage Among them, talent is a key In the daily production and operation of enterprises, the accumulation of professional knowledge and experience of core technicians, large-scale equipment operators, CNC machine operators and other talents plays an important role in improving product quality and production efficiency However, due to the particularity of pharmaceutical machinery industry, professional talents are not directly proportional to the needs of enterprises Therefore, pharmaceutical machinery enterprises can establish incentive mechanism and welfare mechanism, introduce, train and retain talents, so as to maintain the stability of core technical personnel Conclusion: the quarter of 2017 has ended Judging from the financial statements of the pharmaceutical machinery giants such as dongfelong, truking technology and Qianshan pharmaceutical machinery, the performance has increased, and they are constantly exploring and seeking new business models This also brings an inspiration to the pharmaceutical machinery industry Under the trend of intelligent prevalence, enterprises can inject new life into traditional business, actively explore new markets and new fields In order to survive in the fierce market competition, pharmaceutical machinery enterprises need to conform to the trend, analyze the risks faced according to their own situation and make practical adjustments.